Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2021 Sep 2;35(12):3626. doi: 10.1038/s41375-021-01396-x

Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Francisco Cervantes 1,, David M Ross 2, Atanas Radinoff 3, Francesca Palandri 4, Alexandr Myasnikov 5, Alessandro M Vannucchi 6, Pierre Zachee 7, Heinz Gisslinger 8, Norio Komatsu 9, Lynda Foltz 10, Francesco Mannelli 6, Francesco Passamonti 11, Geralyn Gilotti 12, Islam Sadek 12, Ranjan Tiwari 13, Evren Zor 14, Haifa Kathrin Al-Ali 15
PMCID: PMC9119245  PMID: 34475521

Correction to: Leukemia

10.1038/s41375-021-01261-x

Following the publication of this article, the authors noted a minor error in the patient numbers on the lower axis of Fig. 4, panel A. This has now been corrected and the amended figure included below. This error does not impact the scientific validity of the manuscript or any conclusions drawn in it.

graphic file with name 41375_2021_1396_Fig1_HTML.jpg

Footnotes

The original article can be found online at 10.1038/s41375-021-01261-x.


Articles from Leukemia are provided here courtesy of Nature Publishing Group

RESOURCES